The Biotech Everyone Gave Up On Is Quietly Rebuilding
Biogenās (BIIB) biggest drugs are dying. The stock is climbing anyway. For a company whose old engine, the big multiple sclerosis names, has been winding down for years, that does not add up on the surface. So what is the market starting to see that the headlines are not? Look at what Biogen has actually…
